Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries.

Rebitschek FG, Pashayan N, Widschwendter M, Wegwarth O.

PLoS One. 2019 Jun 12;14(6):e0218188. doi: 10.1371/journal.pone.0218188. eCollection 2019.

2.

Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey.

Wegwarth O, Pashayan N, Widschwendter M, Rebitschek FG.

BMC Public Health. 2019 May 30;19(1):667. doi: 10.1186/s12889-019-6994-8.

3.

What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries.

Wegwarth O, Widschwendter M, Cibula D, Sundström K, Portuesi R, Lein I, Rebitschek FG; FORECEE (4C) consortium.

BMJ Open. 2018 Dec 28;8(12):e023789. doi: 10.1136/bmjopen-2018-023789.

4.

Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider.

Lévesque E, Kirby E, Bolt I, Knoppers BM, de Beaufort I, Pashayan N, Widschwendter M.

Public Health Genomics. 2018;21(1-2):37-44. doi: 10.1159/000492663. Epub 2018 Sep 17.

5.

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Polo SH, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, de Fazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Mina F, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J; AOCS Group, Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M.

J Pathol Clin Res. 2018 Oct;4(4):250-261. doi: 10.1002/cjp2.109. Epub 2018 Sep 21.

6.

Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.

Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L.

Int J Cancer. 2018 Dec 1;143(11):2932-2942. doi: 10.1002/ijc.31659. Epub 2018 Oct 3.

PMID:
29978915
7.

Accounting for differential variability in detecting differentially methylated regions.

Wang Y, Teschendorff AE, Widschwendter M, Wang S.

Brief Bioinform. 2019 Jan 18;20(1):47-57. doi: 10.1093/bib/bbx097.

PMID:
29912290
8.

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review.

Alblas M, Velt KB, Pashayan N, Widschwendter M, Steyerberg EW, Vergouwe Y.

Crit Rev Oncol Hematol. 2018 Jun;126:92-99. doi: 10.1016/j.critrevonc.2018.03.023. Epub 2018 Mar 31. Review.

9.

DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants.

Gao Y, Widschwendter M, Teschendorff AE.

EBioMedicine. 2018 May;31:243-252. doi: 10.1016/j.ebiom.2018.04.025. Epub 2018 May 4.

10.

A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix.

Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, Jevons S, Lovat LB, Beck S, Widschwendter M, Teschendorff AE.

Epigenomics. 2018 Jul;10(7):925-940. doi: 10.2217/epi-2018-0037. Epub 2018 Apr 25.

11.

Epigenome-based cancer risk prediction: rationale, opportunities and challenges.

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium.

Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Review.

12.

Psychosocial adversity and socioeconomic position during childhood and epigenetic age: analysis of two prospective cohort studies.

Lawn RB, Anderson EL, Suderman M, Simpkin AJ, Gaunt TR, Teschendorff AE, Widschwendter M, Hardy R, Kuh D, Relton CL, Howe LD.

Hum Mol Genet. 2018 Apr 1;27(7):1301-1308. doi: 10.1093/hmg/ddy036.

13.

The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer.

Widschwendter M, Zikan M, Wahl B, Lempiäinen H, Paprotka T, Evans I, Jones A, Ghazali S, Reisel D, Eichner J, Rujan T, Yang Z, Teschendorff AE, Ryan A, Cibula D, Menon U, Wittenberger T.

Genome Med. 2017 Dec 22;9(1):116. doi: 10.1186/s13073-017-0500-7.

14.

Methylation patterns in serum DNA for early identification of disseminated breast cancer.

Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, Gentry-Maharaj A, Zikan M, Cibula D, Eichner J, Alunni-Fabbroni M, Koch J, Janni WJ, Paprotka T, Wittenberger T, Menon U, Wahl B, Rack B, Lempiäinen H.

Genome Med. 2017 Dec 22;9(1):115. doi: 10.1186/s13073-017-0499-9.

15.
16.

Are objective measures of physical capability related to accelerated epigenetic age? Findings from a British birth cohort.

Simpkin AJ, Cooper R, Howe LD, Relton CL, Davey Smith G, Teschendorff A, Widschwendter M, Wong A, Kuh D, Hardy R.

BMJ Open. 2017 Nov 1;7(10):e016708. doi: 10.1136/bmjopen-2017-016708.

17.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

18.

Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting.

Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D.

Ultrasound Obstet Gynecol. 2018 Jun;51(6):829-835. doi: 10.1002/uog.18918. Epub 2018 Jun 4.

19.

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.

Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA.

ESMO Open. 2017 Jan 31;1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016.

20.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

21.

Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours - a randomised controlled trial of RMI/RCOG vs Simple Rules.

Nunes N, Ambler G, Foo X, Naftalin J, Derdelis G, Widschwendter M, Jurkovic D.

Br J Cancer. 2017 Feb 28;116(5):584-591. doi: 10.1038/bjc.2017.17. Epub 2017 Feb 2.

22.

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.

Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF.

Br J Cancer. 2017 Feb 14;116(4):501-508. doi: 10.1038/bjc.2016.433. Epub 2017 Jan 12.

23.

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM.

Oncotarget. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013.

24.

The natural history of endometrial polyps.

Wong M, Crnobrnja B, Liberale V, Dharmarajah K, Widschwendter M, Jurkovic D.

Hum Reprod. 2017 Feb;32(2):340-345. doi: 10.1093/humrep/dew307. Epub 2016 Dec 18.

PMID:
27994000
25.

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.

Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA.

Gynecol Oncol. 2017 Jan;144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001. Epub 2016 Nov 5.

PMID:
27825669
26.

Correlation of an epigenetic mitotic clock with cancer risk.

Yang Z, Wong A, Kuh D, Paul DS, Rakyan VK, Leslie RD, Zheng SC, Widschwendter M, Beck S, Teschendorff AE.

Genome Biol. 2016 Oct 3;17(1):205.

27.

The lncRNA HOTAIR impacts on mesenchymal stem cells via triple helix formation.

Kalwa M, Hänzelmann S, Otto S, Kuo CC, Franzen J, Joussen S, Fernandez-Rebollo E, Rath B, Koch C, Hofmann A, Lee SH, Teschendorff AE, Denecke B, Lin Q, Widschwendter M, Weinhold E, Costa IG, Wagner W.

Nucleic Acids Res. 2016 Dec 15;44(22):10631-10643. Epub 2016 Sep 14.

28.

The multi-omic landscape of transcription factor inactivation in cancer.

Teschendorff AE, Zheng SC, Feber A, Yang Z, Beck S, Widschwendter M.

Genome Med. 2016 Aug 25;8(1):89. doi: 10.1186/s13073-016-0342-8.

29.

Menopause accelerates biological aging.

Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CD, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes TL, Horvath S.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9327-32. doi: 10.1073/pnas.1604558113. Epub 2016 Jul 25.

30.

DNA Methylation Signatures in Vaginal Fluid Samples for Detection of Cervical and Endometrial Cancer.

Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, Macdonald N, Teschendorff AE, Widschwendter M.

Int J Gynecol Cancer. 2016 Jun 2. [Epub ahead of print]

PMID:
27258725
31.

Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer.

Gao Y, Jones A, Fasching PA, Ruebner M, Beckmann MW, Widschwendter M, Teschendorff AE.

Clin Epigenetics. 2016 Jun 1;8:63. doi: 10.1186/s13148-016-0231-4. eCollection 2016. No abstract available.

32.

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS.

Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. Epub 2016 Jun 3.

PMID:
27256106
33.

Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.

Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M.

Nat Commun. 2016 May 24;7:11620. doi: 10.1038/ncomms11620.

34.

Epigenetic drift, epigenetic clocks and cancer risk.

Zheng SC, Widschwendter M, Teschendorff AE.

Epigenomics. 2016 May;8(5):705-19. doi: 10.2217/epi-2015-0017. Epub 2016 Apr 22. Review.

PMID:
27104983
35.

Stochastic epigenetic outliers can define field defects in cancer.

Teschendorff AE, Jones A, Widschwendter M.

BMC Bioinformatics. 2016 Apr 22;17:178. doi: 10.1186/s12859-016-1056-z.

36.
37.

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.

Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ.

J Natl Cancer Inst. 2016 Jan 27;108(3). doi: 10.1093/jnci/djv347. Print 2016 Mar.

38.

DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer.

Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M.

Nat Commun. 2016 Jan 29;7:10478. doi: 10.1038/ncomms10478.

39.

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ.

Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Erratum in: Lancet. 2016 Mar 5;387(10022):944. Erratum in: Lancet. 2016 Mar 5;387(10022):944.

40.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S.

Genome Med. 2015 Dec 15;7:128. doi: 10.1186/s13073-015-0246-z.

41.

The integrative epigenomic-transcriptomic landscape of ER positive breast cancer.

Gao Y, Jones A, Fasching PA, Ruebner M, Beckmann MW, Widschwendter M, Teschendorff AE.

Clin Epigenetics. 2015 Dec 9;7:126. doi: 10.1186/s13148-015-0159-0. eCollection 2015. Erratum in: Clin Epigenetics. 2016;8:63.

42.

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers.

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M.

PLoS One. 2015 Dec 2;10(12):e0143178. doi: 10.1371/journal.pone.0143178. eCollection 2015.

43.

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.

Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC.

EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015 Oct.

44.

A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.

Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L.

EBioMedicine. 2015 Sep 9;2(10):1318-30. doi: 10.1016/j.ebiom.2015.08.034. eCollection 2015 Oct.

45.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

46.

Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent.

Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L.

PLoS One. 2015 Oct 21;10(10):e0139013. doi: 10.1371/journal.pone.0139013. eCollection 2015.

47.

Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer.

Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, Anjum S, Hardy R, Salvesen HB, Thirlwell C, Janes SM, Kuh D, Widschwendter M.

JAMA Oncol. 2015 Jul;1(4):476-85. doi: 10.1001/jamaoncol.2015.1053. Erratum in: JAMA Oncol. 2015 Jul;1(4):544.

PMID:
26181258
48.

An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer.

Yang Z, Jones A, Widschwendter M, Teschendorff AE.

Genome Biol. 2015 Jul 14;16:140. doi: 10.1186/s13059-015-0699-9.

49.

Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.

Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, Menon U.

BJOG. 2016 May;123(6):1012-20. doi: 10.1111/1471-0528.13447. Epub 2015 May 29.

50.

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.

J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.

Supplemental Content

Loading ...
Support Center